Infectologia

Tóquio temia que os Jogos Olímpicos disseminassem o COVID; os números sugerem que isso não ocorreu.

9 Ago, 2021 | 11:33h

Tokyo feared Games would spread COVID; numbers suggest that didn’t happen – Reuters

 

Comentário no Twitter

Before the #Olympics began, Japan feared that the Games might spread COVID-19, introduce new variants and overwhelm the medical system. The infection numbers from inside the Olympic 'bubble' tell a different story https://t.co/EsIxj3gsNx

— Reuters (@Reuters) August 7, 2021

 

---

COVID: OMS propõe uma pausa temporária nas doses de reforço para poder vacinar os países mais pobres – isso é justificável?

9 Ago, 2021 | 11:32h

COVID: WHO calls for moratorium on booster shots – is it justifiable? – The Conversation

Conteúdo relacionado: Covid: WHO calls for booster pause to vaccinate poorer nations.

 

Comentário no Twitter

The authors put it well: Even if affluent countries prioritize boosters for the vulnerable, 'the degree of additional benefit…is uncertain.' Yet we know 'vaccines could do a huge amount of good for the large number of vulnerable ppl who've not yet received a single dose.' https://t.co/6qNV6pzDDk

— Tedros Adhanom Ghebreyesus (@DrTedros) August 7, 2021

 

---

Reforços da vacina contra COVID: questões mais importantes.

9 Ago, 2021 | 11:30h

COVID vaccine boosters: the most important questions – Nature

 

Comentário no Twitter

I agree with @nataliexdean: “We just don’t have clear evidence of enough of a loss of efficacy to change our focus or distract from the main goal, which is trying to get as many people first doses” as possible." https://t.co/FEKB4vg0Dz

— Sanghyuk Shin (@sanghyuk_shin) August 6, 2021

 

---

Mais dados mostram que uma dose da vacina da Pfizer pode ser suficiente para pessoas que já tiveram COVID.

9 Ago, 2021 | 11:29h

Comentário: One Dose of Pfizer Vaccine May Be Enough for Folks Who’ve Had COVID – HealthDay

Estudo original: SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine – JAMA Network Open

Conteúdos relacionados:

Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.

Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

Spain to give just one vaccine dose to under 55-year olds who had COVID-19

Perspective: Is one vaccine dose enough after COVID-19 infection?

France’s health authority recommends single vaccine shot for people who have had COVID-19

Covid-19: People who have had infection might only need one dose of mRNA vaccine

 

Comentário no Twitter

SARS-CoV-2 Antibody Responses After 1 and 2 Doses of the BNT162b2 Vaccine https://t.co/ARMdH8Yboo via @JAMANetworkOpen part of @JAMANetwork Small study but one that confirms the policy of many European countries in which one dose of vaccine is sufficient after having COVID.

— Carlos del Rio (@CarlosdelRio7) August 7, 2021

 

---

Relato de caso | Síndrome de vazamento capilar sistêmico após vacinação com a vacina da Oxford–AstraZeneca.

9 Ago, 2021 | 11:27h

Systemic capillary leak syndrome afer ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination – Canadian Medical Association Journal

---

Revisão | Transmissão de infecções durante a ressuscitação cardiopulmonar.

9 Ago, 2021 | 11:05h

Transmission of Infections during Cardiopulmonary Resuscitation – Clinical Microbiology Reviews

---

[Preprint] Estudo randomizado | Estratégias respiratórias não invasivas na insuficiência respiratória aguda em pacientes com COVID-19 – CPAP reduziu o desfecho composto de entubação ou morte em 30 dias; o uso do cateter nasal de alto fluxo não foi associado a desfechos melhores.

6 Ago, 2021 | 11:58h

An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 – medRxiv

Comentário: Covid: Pressured oxygen reduces ventilator need – BBC

 

Comentário no Twitter (fio – clique para saber mais)

RECOVERY-RS results out, and confirm what most of us have been doing:

CPAP reduces intubation/mortality by 28% compared with no CPAP/HFNO (composite outcome, mostly intubation)
Nasal high flow not so successful

1/https://t.co/bcB2sTdAsu pic.twitter.com/fvT8IbyxUr

— 𝚃𝚘𝚖 𝙻𝚊𝚠𝚝𝚘𝚗 💙 (@LawtonTri) August 5, 2021

 

---

Revisão sistemática | “Rendesivir provavelmente tem pouco ou nenhum efeito sobre a mortalidade por todas as causas em até 28 dias em adultos hospitalizados com infecção por SARS-CoV-2. Não estamos certos a respeito dos efeitos deste medicamento sobre a melhora ou a piora clínica.”

6 Ago, 2021 | 11:55h

Remdesivir for the treatment of COVID‐19 – Cochrane Library

Resumo: Remdesivir for the treatment of COVID-19 – Cochrane Library

 

Comentário no Twitter (fio – clique para saber mais)

JUST PUBLISHED – Is #remdesivir an effective treatment for #COVID19? https://t.co/ntgfDQjMqs This @CochraneHaem systematic review looked at this antiviral medicine to see if it's an effective treatment for people in hospital w #COVID & if it causes unwanted effects. 1/5 pic.twitter.com/UtIW83uTtn

— The Cochrane Library (@CochraneLibrary) August 5, 2021

 

---

Tratamento com dexametasona e tocilizumabe reduz consideravelmente os níveis de proteína C reativa e procalcitonina, dificultando a detecção de infecções bacterianas secundárias em pacientes com COVID-19.

6 Ago, 2021 | 11:52h

Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients – Critical Care

---

Imagem clínica | Mucormicose após COVID-19 em paciente com diabetes.

6 Ago, 2021 | 11:51h

Mucormycosis after COVID-19 in a patient with diabetes – The Lancet

Conteúdos relacionados:

COVID-19 and mucormycosis superinfection: the perfect storm.

ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.

The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested by the authors.

Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India – Uncontrolled diabetes mellitus was the most common underlying disease; improper glucocorticoid use was independently associated with the disease.

Opinion | “Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing” – improper use of antibiotics and higher than usual doses of corticosteroids may be contributing to the emergence of mucormycosis and other fungal co-infections.

What is mucormycosis, the fungal infection affecting COVID patients in India?

[Preprint] The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries.

Mucormycosis: The ‘black fungus’ maiming Covid patients in India

Global Guideline for the Diagnosis and Management of Mucormycosis

---